Home > Healthcare > Pharmaceuticals > Finished Drug Form > Plasma Derived Therapy Market

Plasma Derived Therapy Market Trends

Report ID: GMI5271
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Plasma Derived Therapy Market Trends

The increasing investments by the plasma industry in research and development activities to create innovative plasma therapies which result in cutting-edge medical procedures that help patients will act as a positive impact rendering factor for market progress. For instance, Grifols dedicated its USD 360 million to increase its capacity for producing plasma-derived treatments. With the support of this investment, the company has been able to improve its plasma fractionation and purification capabilities.
Plasma-derived therapy industry is driven by the growing adoption of immunoglobulin across the world. Plasma-derived immunoglobulins demand has increased owing to an increase in the recognition and treatment of immune deficiencies. It has emerged as an important treatment option in a variety of clinical settings, including autoimmune conditions and acute inflammatory.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Plasma derived therapy industry size exceeded USD 16.8 billion in 2022 and is set to expand at 7.5% CAGR from 2023-2032 owing to the rising prevalence of rare diseases including primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), and von Willebrand disease.

Plasma derived therapy industry from the immunoglobulin segment accounted for 48.1% revenue share in 2022 and is estimated to exhibit steady growth through 2032 attributed to the increasing usage for the treatment of several complex diseases globally.

North America held over 52.2% revenue share of the plasma derived therapy industry in 2022 and is estimated to expand at a robust CAGR through 2032 driven by favorable government initiatives and the growing awareness about plasma-derived therapies among blood donors.

Few leading plasma derived therapy industry players are CSL Behring, Takeda Pharmaceutical Company Limited, Biotest AG, Octapharma, BPL, ADMA Biologics, Grifols, SA, Kamada Pharmaceuticals, SK Plasma